ZANTAC 300
LOE ApproachingNDAORALCAPSULE
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 300 is an oral capsule histamine H2-receptor antagonist approved by GSK in 1994 for acid-related disorders. The product mechanism reduces gastric acid secretion by blocking H2 receptors on parietal cells. It addresses indications common to the H2-blocker class, including peptic ulcer disease and gastroesophageal reflux disease.
LOE Approaching
Declining
LOE-approaching small molecule indicates smaller brand team focus on maintenance and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZANTAC 300 roles are limited in number and primarily focused on defending existing market share and managing transition to generics rather than driving growth. Career opportunities are best suited for professionals with managed-care negotiation, mature-product strategy, or cost-management expertise.
Brand ManagerField Sales Representative
Worked on ZANTAC 300 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.